Mark Kaplan, MD
Allergy & Immunology · Gurnee, ILNPI 1861591661
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 470 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,074 and has fallen 95.7% since, to $89 in 2025.
Across 470 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Sanofi$1K
- Optinose US, Inc.$780
- Regeneron Healthcare Solutions, Inc.$727
- Genentech USA, Inc.$456
- plus $3K from 24 others
What the payments were for
- Food & beverage$9,69399%
- Education$841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 83 | $1,946 |
| GSK | 91 | $1,449 |
| Sanofi | 45 | $1,410 |
| Optinose US, Inc. | 40 | $780 |
| Regeneron Healthcare Solutions, Inc. | 30 | $727 |
| Genentech USA, Inc. | 28 | $456 |
| Boehringer Ingelheim | 20 | $421 |
| Kaleo, Inc. | 14 | $326 |
| CSL Behring | 13 | $275 |
| Pfizer | 26 | $272 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $237 |
| Teva Pharmaceuticals USA, Inc. | 13 | $210 |
| Alk-abello, Inc | 10 | $207 |
| Novartis | 8 | $175 |
| Biocryst US Sales Co., LLC | 6 | $135 |
| Amgen | 5 | $112 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $89 |
| Octapharma USA, Inc. | 1 | $81 |
| ADMA Biomanufacturing LLC | 4 | $68 |
| Aimmune Therapeutics, Inc. | 3 | $60 |
| Blueprint Medicines Corporation | 3 | $53 |
| Shire North American Group Inc | 3 | $47 |
| Covis Pharma GmbH | 2 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Hikma Pharmaceuticals USA | 2 | $40 |
| Merck | 2 | $38 |
| LEO Pharma Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $20 |
| Phadia US Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,777 in reported general payments places this provider in the 75th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 29 | $137,986 |
| Dupixent PenDupilumab | 13 | $59,913 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $55,438 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $18,739 |
| Advair HfaFluticasone Propion/Salmeterol | 39 | $16,551 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $14,674 |
| Spiriva RespimatTiotropium Bromide | 17 | $14,296 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $6,571 |
| Pulmicort FlexhalerBudesonide | 18 | $5,616 |
| Ipratropium Bromide | 160 | $5,403 |
| Azelastine Hcl | 161 | $4,957 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,743 |
| Epinephrine | 18 | $4,088 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $3,717 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $2,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,449 | $74,17783 claims |
| AstraZenecaBreztri Aerosphere, Pulmicort Flexhaler, Symbicort | $1,946 | $25,03348 claims |
| Boehringer IngelheimSpiriva Respimat | $421 | $14,29617 claims |
| Hikma Pharmaceuticals USAEpinephrine | $40 | $4,08818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 161 allergy & immunology providers in Illinois.
Other allergy & immunology in Gurnee
- Dareen SiriNormal$1.5M
- Priya BansalSaint Charles$1.3M
- Anju PetersChicago$563K
- Giselle MosnaimChicago$331K
- Patrick WinShiloh$258K
- Amanda SalihChicago$160K
- Rebecca HoffmanWilmette$160K
- Juanita MoraChicago$147K
- Sonali MajmudarAlgonquin$136K
- Zachary RubinElmhurst$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.